Articles by Guru P. Sonpavde, MD
The panel elaborates on what excites them most about the future of UC research, highlighting promising advancements.
The panel considers the evolving role of ctDNA in guiding adjuvant therapy decisions, highlighting IMvigor011 and MODERN.
The panel shares the NIAGARA findings and results from RETAIN-2 on dose-dense MVAC for bladder preservation.
The panel covers 2L treatment options for mUC post-EV/pembro, with emphasis on platinum-based chemo and targeted therapy.
The panel debates patient selection, alternative regimens, and the balance between escalation and de-escalation strategies.
The panel weighs the impact of long-term survival data from the EV-302 trial, with significant improvements in OS.
Dr. Sonpavde provides an update on the latest analysis from the phase 3 global study of EV in combination with pembro.
Dr. Sonpavde showcases a phase I/Ib clincial trial on the safety of a neoadjuvant darolutamide and relugolix combination.
Dr. Sonpavde provides an overview of a phase I/II trial in progress on V940 (mRNA-4157) for resected high-risk MIUC.
Dr. Sonpavde analyzes the efficacy of the SMARCA2 degrader, nivolumab plus gemcitabine and cisplatin, and more.
Dr. Guru Sonpavde discusses urothelial carcinoma trials AMBASSADOR, NIAGARA, CM901, and PRT3789.
Dr. Sonpavde shares his thoughts on first-line therapy for aUC, including trials like CheckMate 274, AMBASSADOR, and NIAGRA.
Drs. Ambinder and Sonpavde provide an update for CheckMate 901, characterizing treatment benefit in responders.
Dr. Sonpavde provides an overview of the potential of nivo/gem-cis for patients with mUC who are ineligible for EV/pembro.
The panel concludes with their forward-thinking thoughts on the impending direction of urothelial carcinoma treatment.
The panel considered the latest available data pertaining to EV, atezolizumab, erdafitinib, and other therapy options.
The panel highlighted new data released on SG, including real-world findings and relevant results from the UNITE trial.
The panel transitioned to the AMBASSADOR trial findings and other adjuvant treatment considerations for urothelial carcinoma.
The panel weighed in on treatment selection after patient progression on EV/pembrolizumab.
The panel considered treatment options for patients with mUC who are not eligible for EV/pembrolizumab.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.